Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment. Beth Greenfield. January 22, 2025 at 8:28 PM ... Spravato is made from esketamine, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
Esketamine is the second drug to be approved for treatment-resistant depression by the FDA, following olanzapine/fluoxetine (Symbyax) in 2009. [ 25 ] [ 50 ] Other agents, like the atypical antipsychotics aripiprazole (Abilify) and quetiapine (Seroquel), have been approved for use in the adjunctive therapy of major depressive disorder in people ...
An enantiomer of ketamine – esketamine commercially sold as Spravato – was approved as an antidepressant by the European Medicines Agency in 2019. [63] Esketamine was approved as a nasal spray for treatment-resistant depression in the United States [64] and elsewhere in 2019 (see Esketamine and Depression). The Canadian Network for Mood and ...
The drug is a novel esketamine analogue and conjugate that acts as a prodrug of esketamine. [3] Esketamine, and by extension XW10508, is an NMDA receptor antagonist and indirect AMPA receptor activator. [1] [5] XW10508 is being developed as once-daily orally administered extended-release and immediate-release formulations with misuse resistance ...
FDA approves first-of-its-kind medicine. Erin Pflaumer. January 22, 2025 at 6:48 AM ... The main ingredient for the spray is esketamine hydrochloride, which is the “chemical cousin” of ketamine.
The US Food and Drug Administration (FDA) first approved the use of intranasal esketamine —an enantiomer of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019, [11] leading to the creation and expansion of telemedicine-based companies that practice KAP, such as Mindbloom. [12]